Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future

Endocrine resistance in hormone receptor positive breast cancer patients urges us to develop novel approaches such as inhibitors of the cyclin-dependent kinases (CDK) 4/6 to reverse its resistance. Nowadays, three selective CDK4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) are approved by...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiu, Xu, Di, Li, Xingjiang, Zhang, Jian, Xu, Weilin, Hou, Junchen, Zhang, Wei, Tang, Jinhai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856891/
https://www.ncbi.nlm.nih.gov/pubmed/31777590
http://dx.doi.org/10.7150/jca.33079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856891/
https://www.ncbi.nlm.nih.gov/pubmed/31777590
http://dx.doi.org/10.7150/jca.33079

Ejemplares similares